Gossamer Bio (GOSS) Stock Price, News & Analysis

Company Overview

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies. In addition to these clinical-stage assets, Gossamer Bio maintains several earlier-stage programs targeting pathways such as integrin and TGF-β signaling. The company’s R&D efforts are supported by a combination of in-house research capabilities and external collaborations with academic centers and contract research organizations.

Gossamer Bio completed its initial public offering in July 2019 and has since advanced multiple clinical trials across North America and selected international sites. The company is led by President and Chief Executive Officer Thomas A. Whiting, a veteran of the biopharmaceutical industry with over 25 years of drug development experience. Under his leadership, Gossamer Bio continues to build a multidisciplinary management team focused on accelerating the translation of scientific insights into therapeutic candidates.

Key Stats

• Today's Range: $2.51 to $2.64
• 50-Day Range: $1.73 to $3.46
• 52-Week Range: $0.66 to $3.60
• Volume: 2.79 million shs
• Average Volume: 4.69 million shs
• Market Capitalization: $584.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

Gossamer Bio Stock Analysis - MarketRank™

Gossamer Bio scored higher than 80% of companies evaluated by MarketBeat, and ranked 202nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Gossamer Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Gossamer Bio has a consensus price target of $8.50, representing about 230.7% upside from its current price of $2.57.

Amount of Analyst Coverage

Gossamer Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Gossamer Bio are expected to decrease in the coming year, from ($0.28) to ($0.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Gossamer Bio is -4.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Gossamer Bio is -4.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Gossamer Bio has a P/B Ratio of 19.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.55% of the outstanding shares of Gossamer Bio have been sold short.

Short Interest Ratio / Days to Cover

Gossamer Bio has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Gossamer Bio has recently increased by 8.80%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Gossamer Bio does not currently pay a dividend.

Dividend Growth

Gossamer Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.67

Percentage of Shares Shorted

10.55% of the outstanding shares of Gossamer Bio have been sold short.

Short Interest Ratio / Days to Cover

Gossamer Bio has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Gossamer Bio has recently increased by 8.80%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.70

News Sentiment

Gossamer Bio has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Gossamer Bio this week, compared to 3 articles on an average week.

Search Interest

57 people have searched for GOSS on MarketBeat in the last 30 days. This is an increase of 111% compared to the previous 30 days.

MarketBeat Follows

6 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Gossamer Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.70% of the stock of Gossamer Bio is held by insiders.

Percentage Held by Institutions

81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GOSS Stock Analysis - Frequently Asked Questions

How have GOSS shares performed this year?

Gossamer Bio's stock was trading at $0.9046 on January 1st, 2025. Since then, GOSS stock has increased by 184.1% and is now trading at $2.57.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) issued its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.01. The company had revenue of $11.49 million for the quarter, compared to analyst estimates of $4.12 million. Gossamer Bio had a negative trailing twelve-month return on equity of 1,774.72% and a negative net margin of 344.81%.

When did Gossamer Bio IPO?

Gossamer Bio (GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

How do I buy shares of Gossamer Bio?

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Gossamer Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gossamer Bio investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 10/06/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GOSS
• CIK: 1728117
• Web: www.gossamerbio.com
• Phone: (858) 684-1300
• Fax: N/A
• Employees: 180
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Gossamer Bio: $8.50
• High Price Target: $11.00
• Low Price Target: $5.00
• Potential Upside/Downside: +230.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.53 million
• Net Margins: -344.81%
• Pretax Margin: -353.62%
• Return on Equity: -1,774.72%
• Return on Assets: -46.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.40
• Quick Ratio: 4.40

Sales & Book Value

• Annual Sales: $114.70 million
• Price / Sales: 5.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.13 per share
• Price / Book: 19.77

Miscellaneous

• Outstanding Shares: 227,380,000
• Free Float: 212,146,000
• Market Cap: $584.37 million
• Optionable: Optionable
• Beta: 1.94